Closing the Innovation Gap in Drug Development in Japan Through Academia and Industry Collaboration
Japan is home to world class academic research and a rich ecosystem of scientific discovery. Yet many promising innovations originating in academia struggle to progress into clinical drug development in Japan and, ultimately, patient benefit. This disconnect, often described as an “innovation gap” between academic and industry research, continues to contribute to challenges such as drug lag and drug loss in Japan’s healthcare landscape.
A recent article in DIA Global Forum explores how closer, more direct collaboration between academic and industry researchers in Japan could help address these systemic challenges in Japan’s drug development ecosystem. Makoto Nagaoka, Senior Director, Head of Regulatory Affairs Japan for Fortrea worked with the DIA Japan Open Innovation Community, to test the hypothesis: Direct, in-person scientific exchange between academic and industry researchers, within the familiar setting of a corporate research facility, could dismantle communication barriers, foster collaboration, and accelerate the societal implementation of academic discoveries.
“As part of the DIA Japan Open Innovation Community's activities, we invited individuals involved in drug R&D from industry, government, and academia to visit corporate research laboratories and engage in direct dialogue with corporate researchers about drug R&D in Japan. I’m proud to be able to share the interesting insights we gained”
- Makoto Nagaoka, Senior Director, Head of Regulatory Affairs Japan
Understanding the Key Collaboration Challenges
While Japanese academic institutions produce high quality research, comparatively few of these discoveries progress into approved therapies. A key contributor is the limited interaction between academic researchers and industry teams early in the research lifecycle. Differences in incentives, expectations, and communication styles—combined with low mobility between sectors—can create barriers to collaboration long before development pathways are clearly defined.
As the article outlines, academic researchers often focus on publication, scientific recognition, and securing future funding, while industry prioritizes translation, scalability, and regulatory viability. Without early dialogue, promising research “seeds” may fail to develop into viable clinical programs.
How Academic–Industry Collaboration Can Accelerate Innovation
The case study presented in DIA Global Forum examined a practical approach to overcoming these barriers: bringing academic and industry researchers together in a shared physical space to engage in direct, face to face scientific exchange. By meeting on common ground and speaking a shared scientific language, participants were able to build mutual understanding, challenge assumptions, and identify opportunities for collaboration earlier in the development process.
Importantly, the initiative emphasized co creation rather than transactional engagement. Rather than focusing solely on downstream development, the approach encouraged open discussion around scientific hypotheses, translational potential, and real world feasibility, helping bridge the gap between discovery and implementation.
Implications for Japan’s Development Ecosystem
The findings reinforce a broader lesson for drug development in Japan: structural challenges in drug development cannot be solved by policy or funding alone. Meaningful progress also requires cultural and operational shifts that encourage cross sector engagement, shared goals, and trust between academia and industry.
Creating more opportunities for early, open scientific dialogue has the potential to accelerate innovation, improve translational success, and ultimately help bring new therapies to patients sooner.
Turning Innovation into Patient Access: Regulatory Strategy in Japan
As Japan continues to explore new models of collaboration between academia and industry, regulatory strategy remains a critical consideration in translating Japan’s healthcare innovation into patient access.
Fortrea’s regulatory team works with sponsors and research colleagues to help navigate regional requirements, align global development pathways, and support efficient progression from early research through later stage development. We’re driven by a shared commitment to maximize the commercial success of our clients’ innovative therapies and accelerate their delivery to the patients who need them most through regulatory strategy and planning.
If you’d like to discuss how our proficiency can support your development strategy in Japan or globally, get in touch with the Fortrea regulatory team to continue the conversation.